BeiGene
BGNE
#939
Rank
A$32.44 B
Marketcap
$291.65
Share price
-2.73%
Change (1 day)
-5.96%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Cash on Hand

Cash on Hand as of June 2024 : A$4.02 Billion

According to BeiGene 's latest financial reports the company has A$4.02 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

BeiGene - Cash on Hand chart (from 2014 to 2024)

Cash on Hand by year

Year Cash on Hand Change
2023-12-31A$4.65 B-30.08%
2022-12-31A$6.66 B-27%
2021-12-31A$9.12 B50.92%
2020-12-31A$6.04 B330.9%
2019-12-31A$1.40 B-44.49%
2018-12-31A$2.52 B135.72%
2017-12-31A$1.07 B110.03%
2016-12-31A$0.51 B270.29%
2015-12-31A$0.13 B154.28%
2014-12-31A$54.24 M1132.47%
2013-12-31A$4.4 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
A$25.42 M-99.37%๐Ÿ‡บ๐Ÿ‡ธ USA
A$62.94 M-98.43%๐Ÿ‡บ๐Ÿ‡ธ USA